Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 10/20 | 0.36 |
| ▸ | C1R | P00736 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CTSG | P08311 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15357880 | 0.84 | ELANE (0.37) | ELANEC1RCA12CA1CA9 | |
| SCHEMBL12498615 | 0.82 | MAOB (0.48) | CA12CA1CA9L3MBTL1 | |
| SCHEMBL15360228 | 0.79 | CA12 (0.40) | CA12CA1CA9HSD17B10ALDH1A1 | |
| SCHEMBL16783427 | 0.77 | ELANE (0.35) | ELANEC1RPBRM1HSD17B10ALDH1A1 | |
| SCHEMBL15346581 | 0.74 | TP53 (0.40) | BACE1ALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL15346816 | 0.74 | C1R (0.36) | ELANEC1RBACE1LMNAMAPT | |
| SCHEMBL15346675 | 0.74 | DUT (0.35) | BACE1HSD17B10ALDH1A1LMNAKDM4E | |
| SCHEMBL12498752 | 0.73 | DUT (0.37) | BACE1ALDH1A1KDM4EL3MBTL1ALOX15 | |
| SCHEMBL16825630 | 0.72 | ELANE (0.37) | ELANEBACE1PBRM1MAPTKDM4E | |
| SCHEMBL16825632 | 0.71 | ELANE (0.36) | ELANEBACE1PBRM1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944641-B2 | Isoquinolinone derivatives useful in the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2018-04-17 | — | — | US | disclosed |
| US-9944641-B2 | Isoquinolinone derivatives useful in the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2018-04-17 | — | — | US | disclosed |
| US-20170240544-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-08-24 | — | — | US | disclosed |
| US-20170240544-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-08-24 | — | — | US | disclosed |
| US-20170240544-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-08-24 | — | — | US | disclosed |
| EP-3189051-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Pierre Fabre Médicament (FR) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034642-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016034642-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | WO | disclosed |
| US-9029391-B2 | Isoquinoline compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-05-12 | — | — | US | disclosed |
| US-9029391-B2 | Isoquinoline compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-05-12 | — | — | US | disclosed |
| US-9029391-B2 | Isoquinoline compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-05-12 | — | — | US | disclosed |
| US-20130289027-A1 | Isoquinoline Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| US-20130289027-A1 | Isoquinoline Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| US-20130289027-A1 | Isoquinoline Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| WO-2012102985-A1 | ISOQUINOLINE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289027-A1 | Isoquinoline Compounds And Methods For Treating HIV | MAVS, CCR5, NFATC1 | ELANE 1371/4885C1R 4067/4885BACE1 2231/4885 |
| US-20170240544-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | TP53, KRAS, AQP1 | ELANE 1766/4885C1R 4059/4885BACE1 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.